{
  "url": "https://www.morningstar.com/news/pr-newswire/20250808io47222/raysearch-laboratories-interim-report-april-june-2025",
  "authorsByline": "",
  "articleId": "69f9c424da5d42e7bcf18c7a2541ce7c",
  "source": {
    "domain": "morningstar.com",
    "location": {
      "country": "us",
      "state": "IL",
      "county": "Cook County",
      "city": "Chicago",
      "coordinates": {
        "lat": 41.8755616,
        "lon": -87.6244212
      }
    }
  },
  "imageUrl": "https://images.contentstack.io/v3/assets/blt4eb669caa7dc65b2/blta7dd42ebdd7b93b8/61899b34a3c7df383578294c/morningstar-og.png",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-08T01:17:00-05:00",
  "addDate": "2025-08-08T07:09:44.482578+00:00",
  "refreshDate": "2025-08-08T07:09:44.482581+00:00",
  "score": 1.0,
  "title": "RaySearch Laboratories: Interim report April - June 2025",
  "description": "RaySearch Laboratories: Interim report April - June 2025  Morningstar",
  "content": "\u2022 Order backlog amounted to SEK 1,665.3 M (1,790.5) at the end of the period\n\nSIGNIFICANT EVENTS DURING THE SECOND QUARTER\n\u2022 Odense University Hospital in Denmark has placed an order and is increasing the level of automation with the RayStation treatment planning system.\n\u2022 In May, RayStation v2025 was launched, featuring fast automated treatment planning using machine learning* and the ECHO algorithm, as well as expanded support for treatment planning for patients in the upright position.\n\u2022 The Royal Marsden in the United Kingdom was the first clinic in the world to treat a patient using the new adaptive re-planning module in RayStation during online adaptive radiotherapy.\n\u2022 RayStation was used in a groundbreaking clinical milestone at Helsinki University Hospital - the first accelerator-based BNCT treatments in Europe.\n\u2022 In June, RayCare v2025 was launched, featuring powerful functionality enhancements that streamline clinical workflows, improve data management, and strengthen interoperability throughout the treatment continuum.\n\nSIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD\n\u2022 RaySearch and Radiology Oncology Systems, Inc. (ROS) announce strategic partnership with focus on the integration of refurbished linear accelerators with advanced software solutions.\n\u2022 AKSM/Oncology selects RayCare and RayStation for a new cancer center.\n\n*Regulatory approval is required in certain markets; not available for use in the United States or Canada.\n\nFOR FURTHER INFORMATION, PLEASE CONTACT:\n\nThe information contained in this year-end report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on August 8, 2025, at 7:45 a.m. CEST.\n\nCEO Johan L\u00f6f and CFO Nina Gr\u00f6nberg will present RaySearch's interim report for the second quarter of 2025 in a webcast to be held in English on Friday, August 8, 2025, at 10:00-10:30 a.m. CEST.\n\nRaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation\u00ae* treatment planning system (TPS) and the oncology information system (OIS) RayCare\u00ae*. The most recent additions to the RaySearch product line are RayIntelligence\u00ae and RayCommand\u00ae*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.\n\nRaySearch's software has been sold to over 1,100 clinics in 47 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.\n\n*Subject to regulatory clearance in some markets.\n\nThis information was brought to you by Cision http://news.cision.com.\n\nThe following files are available for download:",
  "medium": "Article",
  "links": [
    "https://c212.net/c/link/?t=0&l=en&o=4484478-1&h=2888731881&u=http%3A%2F%2Fnews.cision.com%2F&a=http%3A%2F%2Fnews.cision.com",
    "https://c212.net/c/link/?t=0&l=en&o=4484478-1&h=3453846270&u=https%3A%2F%2Fmb.cision.com%2FMain%2F1102%2F4215728%2F3602856.pdf&a=https%3A%2F%2Fmb.cision.com%2FMain%2F1102%2F4215728%2F3602856.pdf",
    "https://c212.net/c/link/?t=0&l=en&o=4484478-1&h=418126767&u=https%3A%2F%2Fwww.raysearchlabs.com%2F&a=raysearchlabs.com",
    "https://www.prnewswire.com/news-releases/raysearch-laboratories-interim-report-april---june-2025-302525091.html",
    "https://c212.net/c/link/?t=0&l=en&o=4484478-1&h=4169200859&u=https%3A%2F%2Fevents.teams.microsoft.com%2Fevent%2F3be4808f-87b1-4c7d-bed2-926949214dff%4050ba1ecf-6812-4030-81b8-a9b983f4f358&a=RaySearch+Q2%2C+2025",
    "https://c212.net/c/link/?t=0&l=en&o=4484478-1&h=3330193798&u=https%3A%2F%2Fnews.cision.com%2Fraysearch-laboratories%2Fr%2Finterim-report-april---june-2025%2Cc4215728&a=https%3A%2F%2Fnews.cision.com%2Fraysearch-laboratories%2Fr%2Finterim-report-april---june-2025%2Cc4215728"
  ],
  "labels": [],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "treatment planning",
      "weight": 0.100739986
    },
    {
      "name": "fast automated treatment planning",
      "weight": 0.09270564
    },
    {
      "name": "improved cancer treatment",
      "weight": 0.09075403
    },
    {
      "name": "RaySearch Laboratories AB",
      "weight": 0.08113129
    },
    {
      "name": "RaySearch Laboratories",
      "weight": 0.07853848
    },
    {
      "name": "the RayStation treatment planning system",
      "weight": 0.07113966
    },
    {
      "name": "RaySearch",
      "weight": 0.069537856
    },
    {
      "name": "cancer clinics",
      "weight": 0.06715831
    },
    {
      "name": "RayStation",
      "weight": 0.06543294
    },
    {
      "name": "FURTHER INFORMATION",
      "weight": 0.06293765
    }
  ],
  "topics": [],
  "categories": [
    {
      "name": "Health"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Company News",
      "score": 0.81591796875
    },
    {
      "name": "/News/Health News",
      "score": 0.62646484375
    },
    {
      "name": "/Health/Medical Facilities & Services/Other",
      "score": 0.62158203125
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.451904296875
    },
    {
      "name": "/Health/Medical Facilities & Services/Hospitals & Treatment Centers",
      "score": 0.438720703125
    },
    {
      "name": "/Health/Health Foundations & Medical Research",
      "score": 0.403564453125
    },
    {
      "name": "/Health/Medical Devices & Equipment/Other",
      "score": 0.30859375
    }
  ],
  "sentiment": {
    "positive": 0.5439453,
    "negative": 0.026245117,
    "neutral": 0.43017578
  },
  "summary": "RaySearch Laboratories AB (publ) has published its interim report for the second quarter 2025, showing a backlog of SEK 1,665.3 M (1,790.5) at the end of the period. The company's RayStation treatment planning system was launched in May, featuring fast automated treatment planning using machine learning* and the ECHO algorithm, and expanded support for treatment planning for patients in the upright position. The Royal Marsden in the UK was the first clinic in the world to treat a patient using the new adaptive re-planning module in RayStation during online adaptive radiotherapy. In June, RayCare v2025 was launched featuring powerful functionality enhancements that streamline clinical workflows, improve data management, and strengthen interoperability throughout the treatment continuum. The most recent additions to the RaySearch product line are RayIntelligence and RayCommand\u00ae*. The company is obliged to disclose this information under the EU Market Abuse Regulation and the Swedish Securities Market Act.",
  "shortSummary": "RaySearch Laboratories AB (publ) reported a significant increase in orders, advancements in treatment planning, and a strategic partnership with ROS to enhance cancer treatment.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": true,
  "reprintGroupId": "e7ec7e5041b14c13877abb1ca72c9690",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://www.prnewswire.com/news-releases/raysearch-laboratories-interim-report-april---june-2025-302525091.html",
      "text": "RaySearch Laboratories: Interim report April - June 2025\nSTOCKHOLM, Aug. 8, 2025 /PRNewswire/ --\nSECOND QUARTER (APRIL - JUNE 2025)\n- Order intake amounted to SEK 241.2 M (290.3)\n- Net sales amounted to SEK 304.9 (318.9)\n- Operating profit amounted to SEK 36.4 M (79.3)\n- Profit after tax amounted to SEK 30.8 M (61.4)\n- Earnings per share before/after dilution amounted to SEK 0.90 (1.79)\n- Cash flow from operating activities amounted to SEK 70.6 M (154.6)\n- Order backlog amounted to SEK 1,665.3 M (1,790.5) at the end of the period\nHALF-YEAR (JANUARY - JUNE 2025)\n- Order intake amounted to SEK 650.8 M (528.8)\n- Net sales amounted to SEK 636.6 M (576.1)\n- Operating profit amounted to SEK 111.2 M (125.1)\n- Profit after tax amounted to SEK 87.6 M (98.1)\n- Earnings per share before/after dilution amounted to SEK 2.55 (2.86)\n- Cash flow from operating activities amounted to SEK 217.4 M (321.9)\nSIGNIFICANT EVENTS DURING THE SECOND QUARTER\n- Odense University Hospital in Denmark has placed an order and is increasing the level of automation with the RayStation treatment planning system.\n- In May, RayStation v2025 was launched, featuring fast automated treatment planning using machine learning* and the ECHO algorithm, as well as expanded support for treatment planning for patients in the upright position.\n- The Royal Marsden in the United Kingdom was the first clinic in the world to treat a patient using the new adaptive re-planning module in RayStation during online adaptive radiotherapy.\n- RayStation was used in a groundbreaking clinical milestone at Helsinki University Hospital - the first accelerator-based BNCT treatments in Europe.\n- In June, RayCare v2025 was launched, featuring powerful functionality enhancements that streamline clinical workflows, improve data management, and strengthen interoperability throughout the treatment continuum.\nSIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD\n- RaySearch and Radiology Oncology Systems, Inc. (ROS) announce strategic partnership with focus on the integration of refurbished linear accelerators with advanced software solutions.\n- AKSM/Oncology selects RayCare and RayStation for a new cancer center.\n*Regulatory approval is required in certain markets; not available for use in the United States or Canada.\nFOR FURTHER INFORMATION, PLEASE CONTACT:\nJohan L\u00f6f, CEO | Tel: +46 8 510 530 00, e-mail: [email protected]\nNina Gr\u00f6nberg, CFO | Tel: +46 8 510 530 00, e-mail: [email protected]\nThe information contained in this year-end report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on August 8, 2025, at 7:45 a.m. CEST.\nWEBCAST\nCEO Johan L\u00f6f and CFO Nina Gr\u00f6nberg will present RaySearch's interim report for the second quarter of 2025 in a webcast to be held in English on Friday, August 8, 2025, at 10:00-10:30 a.m. CEST.\nLink to webcast: RaySearch Q2, 2025\nAbout RaySearch\nRaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation\u00ae* treatment planning system (TPS) and the oncology information system (OIS) RayCare\u00ae*. The most recent additions to the RaySearch product line are RayIntelligence\u00ae and RayCommand\u00ae*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.\nRaySearch's software has been sold to over 1,100 clinics in 47 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.\n*Subject to regulatory clearance in some markets.\nThis information was brought to you by Cision http://news.cision.com.\nhttps://news.cision.com/raysearch-laboratories/r/interim-report-april---june-2025,c4215728\nThe following files are available for download:\nRaySearch_Q2_Eng |\nSOURCE RaySearch Laboratories\nWANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?\nNewsrooms &\nInfluencers\nDigital Media\nOutlets\nJournalists\nOpted In\nShare this article"
    },
    {
      "url": "https://c212.net/c/link/?t=0&l=en&o=4484478-1&h=3330193798&u=https%3A%2F%2Fnews.cision.com%2Fraysearch-laboratories%2Fr%2Finterim-report-april---june-2025%2Cc4215728&a=https%3A%2F%2Fnews.cision.com%2Fraysearch-laboratories%2Fr%2Finterim-report-april---june-2025%2Cc4215728",
      "text": "Interim report April - June 2025\nSECOND QUARTER (APRIL - JUNE 2025)\n- Order intake amounted to SEK 241.2 M (290.3)\n- Net sales amounted to SEK 304.9 (318.9)\n- Operating profit amounted to SEK 36.4 M (79.3)\n- Profit after tax amounted to SEK 30.8 M (61.4)\n- Earnings per share before/after dilution amounted to SEK 0.90 (1.79)\n- Cash flow from operating activities amounted to SEK 70.6 M (154.6)\n- Order backlog amounted to SEK 1,665.3 M (1,790.5) at the end of the period\nHALF-YEAR (JANUARY - JUNE 2025)\n- Order intake amounted to SEK 650.8 M (528.8)\n- Net sales amounted to SEK 636.6 M (576.1)\n- Operating profit amounted to SEK 111.2 M (125.1)\n- Profit after tax amounted to SEK 87.6 M (98.1)\n- Earnings per share before/after dilution amounted to SEK 2.55 (2.86)\n- Cash flow from operating activities amounted to SEK 217.4 M (321.9)\nSIGNIFICANT EVENTS DURING THE SECOND QUARTER\n- Odense University Hospital in Denmark has placed an order and is increasing the level of automation with the RayStation treatment planning system\n- In May, RayStation v2025 was launched, featuring fast automated treatment planning using machine learning* and the ECHO algorithm, as well as expanded support for treatment planning for patients in the upright position\n- The Royal Marsden in the United Kingdom was the first clinic in the world to treat a patient using the new adaptive re-planning module in RayStation during online adaptive radiotherapy\n- RayStation was used in a groundbreaking clinical milestone at Helsinki University Hospital \u2013 the first accelerator-based BNCT treatments in Europe\n- In June, RayCare v2025 was launched, featuring powerful functionality enhancements that streamline clinical workflows, improve data management, and strengthen interoperability throughout the treatment continuum\nSIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD\n- RaySearch and Radiology Oncology Systems, Inc. (ROS) announce strategic partnership with focus on the integration of refurbished linear accelerators with advanced software solutions\n- AKSM/Oncology selects RayCare and RayStation for a new cancer center\n*Regulatory approval is required in certain markets; not available for use in the United States or Canada.\nFOR FURTHER INFORMATION, PLEASE CONTACT:\nJohan L\u00f6f, CEO Tel: +46 8 510 530 00, e-mail: johan.lof@raysearchlabs.com\nNina Gr\u00f6nberg, CFO Tel: +46 8 510 530 00, e-mail: nina.gronberg@raysearchlabs.com\nThe information contained in this year-end report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on August 8, 2025, at 7:45 a.m. CEST.\nWEBCAST\nCEO Johan L\u00f6f and CFO Nina Gr\u00f6nberg will present RaySearch\u2019s interim report for the second quarter of 2025 in a webcast to be held in English on Friday, August 8, 2025, at 10:00-10:30 a.m. CEST.\nLink to webcast: RaySearch Q2, 2025\nAbout RaySearch\nRaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation\u00ae* treatment planning system (TPS) and the oncology information system (OIS) RayCare\u00ae*. The most recent additions to the RaySearch product line are RayIntelligence\u00ae and RayCommand\u00ae*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.\nRaySearch\u2019s software has been sold to over 1,100 clinics in 47 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.\n* Subject to regulatory clearance in some markets.\nTags:"
    }
  ],
  "argos_summary": "RaySearch Laboratories reported a decrease in order backlog to SEK 1,665.3 million at the end of Q2 2025, alongside a decline in order intake and net sales compared to the previous year. Significant developments included the launch of RayStation v2025 and RayCare v2025, enhancing automation and clinical workflows, respectively. Notable clinical milestones were achieved, such as the first use of adaptive re-planning in the UK and the first accelerator-based BNCT treatments in Europe. Additionally, a strategic partnership with Radiology Oncology Systems, Inc. was announced to integrate refurbished linear accelerators with advanced software.",
  "argos_id": "UOD2IPBCL"
}